Dubai Medical Journal

Published date: Sep 30 2025

Journal Title: Dubai Medical Journal

Issue title: Dubai Medical Journal (DMJ): Volume 8, Issue 3

Pages: 250 - 262

DOI: 10.18502/dmj.v8i3.19851

Huda Omranhudamossa.omran@gmail.comDepartment of Molecular Medicine, Pulse Health Training Center, Al Jenan Medical Center, Arabian Gulf University

Introduction: Anti-Müllerian Hormone (AMH) gene polymorphisms significantly impact ovarian function, follicular development, and fertility outcomes. This review explores the global distribution of AMH gene polymorphisms, emphasizing unique genetic patterns in Arab populations due to high genetic diversity and consanguinity.

Methods: The review examines methodologies such as genetic analysis and hormone level measurement, along with their application in understanding AMH polymorphisms. It integrates findings from diverse populations to explore genetic, hormonal, and clinical correlations.

Results: Findings indicate a distinct distribution of AMH gene polymorphisms in Arab countries. These polymorphisms are associated with variations in hormonal profiles, ovarian reserve, and reproductive outcomes, particularly in assisted reproductive technologies (ART).

Conclusion: AMH gene polymorphisms have profound implications for reproductive health and fertility treatments. Tailored research addressing genetic, environmental, and socioeconomic factors is essential to understanding these polymorphisms and their interactions. This review underscores the importance of genetic screening and highlights potential advancements in personalized medicine and fertility care.

Keywords: anti-müllerian hormone, gene polymorphisms, reproduction, fertility, ART

[1] Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Anti-Müllerian hormone and its role in ovarian function. Mol Cell Endocrinol. 2003;211(1–2):85–90. https://doi.org/10.1016/j.mce.2003.09.024

[2] Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1–2):81–86. https://doi.org/10.1016/j.mce.2004.09.008

[3] Moolhuisjen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: Update on assessing ovarian function. J Clin Endocrinol Metab. 2020:105(11):3361–3373. https://doi.org/10.1210/clinem/dgaa513

[4] Rigon C, Andrisani A, Forzan M, D’Antona D, Bruson A, Cosmi E, et al. Association study of AMH and AMHRII polymorphisms with unexplained infertility. Fertil Steril. 2010 Sep;94(4):1244–1248. https://doi.org/10.1016/j.fertnstert.2009.05.025 PMID: 19539910

[5] Iwase A, Hasegawa Y, Tsukui Y, Kobayashi M, Hiraishi H, Nakazato T, et al. Anti-Müllerian hormone beyond an ovarian reserve marker: The relationship with the physiology and pathology in the life-long follicle development. Front Endocrinol. 2023;14. https://doi.org/10.3389/fendo.2023.1273966

[6] Cohen-Haguenauer O, Picard JY, Mattéi MG, Serero S, Nguyen VC, de Tand MF, et al. Mapping of the gene for anti-müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet. 1987;44(1):2–6. https://doi.org/10.1159/000132332 PMID: 3028714

[7] Unal E, Yıldırım R, Tekin S, Demir V, Onay H, Haspolat YK. A Novel Mutation of AMHR2 in Two Siblings with Persistent Müllerian Duct Syndrome. J Clin Res Pediatr Endocrinol. 2018 Nov;10(4):387–390. doi:10.4274/jcrpe.0013.

[8] Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet. 2020;37:89–100. https://doi.org/10.1007/s10815-019-01622-7

[9] Cate RL. Anti-Müllerian hormone signal transduction involved in Müllerian duct regression. Front Endocrinol. 2022;13. https://doi.org/10.3389/fendo.2022.905324

[10] Visser JA. AMH signaling: From receptor to target gene. Mol Cell Endocrinol. 2003;211(1–2):65–73. https://doi.org/10.1016/j.mce.2003.09.012

[11] Mullen RD, Behringer RR. Molecular genetics of Müllerian duct formation, regression and differentiation. Sex Dev. 2014;8(5):281–296. https://doi.org/10.1159/000364935

[12] Pabalan N, Montagna E, Singian E, Tabangay L, Jarjanazi H, Parente C, et al. Associations of polymorphisms in anti-Müllerian Hormone (AMH Ile49Ser) and its Type II Receptor (AMHRII -482 A>G) on reproductive outcomes and polycystic ovary syndrome: A systematic review and meta-analysis. Cell Physiol Biochem. 2016;39(6):2249–2261. https://doi.org/10.1159/000447918

[13] Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health. 2009 Oct;6(1):17. https://doi.org/10.1186/1742-4755-6-17 PMID:19811666

[14] Jurczak A, Szkup M, Grzywacz A, Safranow K, Grochans E. The relationship between AMH and AMHR2 polymorphisms and the follicular phase in late reproductive stage women. Int J Environ Res Public Health. 2016 Feb;13(2):185. https://doi.org/10.3390/ijerph13020185 PMID:26848671

[15] Colaco S, Achrekar S, Patil A, Sawant U, Desai S, Mangoli V, et al. Association of AMH and AMHR2 gene polymorphisms with ovarian response and pregnancy outcomes in Indian women. J Assist Reprod Genet. 2022 Jul;39(7):1633–1642. https://doi.org/10.1007/s10815-022-02541-w PMID:35713750

[16] Gorsic LK, Kosova G, Werstein B, Sisk R, Legro RS, Hayes MG, et al. Pathogenic anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab. 2017 Aug;102(8):2862–2872. https://doi.org/10.1210/jc.2017-00612 PMID:28505284

[17] Braem MG, Voorhuis M, van der Schouw YT, Peeters PH, Schouten LJ, Eijkemans MJ, et al. Interactions between genetic variants in AMH and AMHR2 may modify age at natural menopause. PLoS One. 2013;8(3):e59819. https://doi.org/10.1371/journal.pone.0059819PMID:23544102

[18] Chen D, Zhu X, Wu J. Can polymorphisms of AMH/AMHR2 affect ovarian stimulation outcomes? A systematic review and meta-analysis. J Ovarian Res. 2020 Sep;13(1):103. https://doi.org/10.1186/s13048- 020-00699-4 PMID:32887648

[19] Zheng MX, Li Y, Hu R, Wang FM, Zhang XM, Guan B. Anti-Müllerian hormone gene polymorphism is associated with androgen levels in Chinese polycystic ovary syndrome patients with insulin resistance. J Assist Reprod Genet. 2016 Feb;33(2):199–205. https://doi.org/10.1007/s10815-015-0641-9 PMID:26732661

[20] Peluso C, Fonseca FL, Gastaldo GG, Christofolini DM, Cordts EB, Barbosa CP, et al. AMH and AMHR2 polymorphisms and AMH serum level can predict assisted reproduction outcomes: A cross-sectional study. Cell Physiol Biochem. 2015;35(4):1401–1412. https://doi.org/10.1159/000373961

[21] Cerra C, Newman WG, Tohlob D, Byers H, Horne G, Roberts SA, et al. AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation. J Assist Reprod Genet. 2016 Aug;33(8):1085–1091. https://doi.org/10.1007/s10815-016-0711-7 PMID:27142041

[22] Melado L, Vitorino R, Coughlan C, Bixio LD, Arnanz A, Elkhatib I, et al. Ethnic and sociocultural differences in ovarian reserve: Age-specific anti-Müllerian hormone values and antral follicle count for women of the Arabian Peninsula. Front Endocrinol (Lausanne). 2021 Oct;12:735116. https://doi.org/10.3389/fendo.2021.735116 PMID:34745004

[23] Motawi TM, Rizk SM, Maurice NW, Maged AM, Raslan AN, Sawaf AH. The role of gene polymorphisms and AMH level in prediction of poor ovarian response in Egyptian women undergoing IVF procedure. J Assist Reprod Genet. 2017 Dec;34(12):1659–1666. https://doi.org/10.1007/s10815-017-1013- 4 PMID:28825151

[24] Ahmed I. Impact of genetic polymorphisms on the degree of ovarian response to gonadotrophin stimulation in patients undergoing ICSI treatment. 2020, Saarland University. doi:10.22028/D291-35851

[25] Rutkowska A, Olsson A, Wilczewska K, Łaczmański Ł, Kuliczkowska-Płaksej J, Jędrzejuk D, et al. Bisphenol A impacts hormonal profile in patients with polycystic ovary syndrome but not in healthy women. Gynecol Reprod Endocrinol Metab. 2020;1(1):43–47. doi:10.53260/grem.201018

[26] Banerjee K, Thind A, Bhatnagar N, Singla B, Agria K, Bajaj P, et al. Effect of reproductive and lifestyle factors on anti-mullerian hormone levels in women of Indian origin. J Hum Reprod Sci. 2022;15(3):259– 271. https://doi.org/10.4103/jhrs.jhrs_79_22 PMID:36341011

[27] Tzeng CR, Huang Z, Asada Y, Zhang C, Ho MT, Li RH, et al. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: A multi-nation, multi-centre, and multi-ethnicity prospective cohort study. Hum Reprod. 2023 Jul;38(7):1368–1378. https://doi.org/10.1093/humrep/dead081 PMID:37105234

[28] Herraiz S, Romeu M, Buigues A, Martínez S, Díaz-García C, Gómez-Seguí I, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril. 2018 Aug;110(3):496–505.e1. https://doi.org/10.1016/j.fertnstert.2018.04.025 PMID:29960701

[29] Karagiorga I, Partsinevelos GA, Mavrogianni D, Anagnostou E, Zervomanolakis I, Kallianidis K, et al. Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti- Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology. J Assist Reprod Genet. 2015 Mar;32(3):357–367. https://doi.org/10.1007/s10815-014-0403-0 PMID:25542251

[30] Colaco S, Achrekar S, Patil A, Sawant U, Desai S, Mangoli V, et al. Association of AMH and AMHR2 gene polymorphisms with ovarian response and pregnancy outcomes in Indian women. J Assist Reprod Genet. 2022 Jul;39(7):1633–1642. https://doi.org/10.1007/s10815-022-02541-wPMID:35713750

[31] Cheng R, Xiong W, Luo X, Chen H, Hu Y, Xu Y, et al. Association of gene polymorphisms in the anti- Müllerian hormone signalling pathway with ovarian function: A systematic review and meta-analysis. Reprod BioMed. 2019;39(3):513–521. https://doi.org/10.1016/j.rbmo.2019.04.010

[32] Peluso C, Fonseca IF, Rodart V, Cavalcanti G, Gastaldo DM, Christofolini CP, et al. AMH: An ovarian reserve biomarker in assisted reproduction. Clinica Chimica Acta. 2014;437:175–182. https://doi.org/10.1016/j.cca.2014.07.029

[33] Kevenaar ME, Themmen AP, Laven JS, Sonntag B, Fong SL, Uitterlinden AG, et al. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod. 2007 Jun;22(6):1547–1554. https://doi.org/10.1093/humrep/dem036 PMID:17337470

[34] Leonte L. Anti-Mullerian hormone (AMH) as a useful marker in diagnosis of polycystic ovary syndrome. Acta Endocrinol (Bucur). 2007;3(1):1–12. https://doi.org/10.4183/aeb.2007.1

[35] Khan MJ, Ullah A, Basit A. Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives. Appl Clin Genet. 2019;12:249–260. https://doi.org/10.2147/TACG.S200341

[36] Anttonen M, Färkkilä A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, et al. Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab Invest. 2011 Nov;91(11):1605–1614. https://doi.org/10.1038/labinvest.2011.116 PMID:21808236